KRAS and neoplasm: This pathway involves the accumulation of inhibitory mutations at the level of tumor-suppressor genes and activating mutations at the level of oncogenes and are associated with colorectal tumors exhibiting MSS, non-CIMP, CIN, absent KRAS and BRAF mutations, and APC mutations.